Effects of kainic acid on seizure susceptibility in the developing brain

1988 ◽  
Vol 39 (1) ◽  
pp. 51-59 ◽  
Author(s):  
Gregory L. Holmes ◽  
James L. Thompson
2011 ◽  
Vol 2011 ◽  
pp. 1-10 ◽  
Author(s):  
Nian Yu ◽  
Qing Di ◽  
Hao Liu ◽  
Yong Hu ◽  
Ying Jiang ◽  
...  

This study was aimed to investigate the effect of NF-κB activity on the seizure susceptibility, brain damage, and P-gp expression in kainic acid- (KA-) induced seizure rats. Male SD rats were divided into saline control group (NS group), KA induced epilepsy group (EP group), and epilepsy group intervened with NF-κB inhibitor-pyrrolidine dithiocarbamate salt (PDTC group) or with dexamethasone (DEX group). No seizures were observed in the rats of NS group. Compared with NS group, increased P-gp expression and NF-κB activation in the rat brain of the EP group were observed after KA micro-injection. Both PDTC and DEX pre-treatment significantly increased the latency to grade III or V seizure onset compared to EP group but failed to show neuron-protective effect as the number of survival neurons didn't significantly differ from that in EP group. Furthermore, PDTC pre-treatment significantly decreased P-gp expression along with NF-κB activation in the hippocampus CA3 area and amygdala complex of rats compared with the EP group, implying that NF-κB activation involved in the seizure susceptibility and seizure induced brain P-gp over-expression. Additionally, DEX pre-treatment only decreased P-gp expression level without inhibition of NF-κB activation, suggesting NF-κB independent pathway may also participate in regulating seizure induced P-gp over-expression.


1994 ◽  
Vol 660 (1) ◽  
pp. 138-143 ◽  
Author(s):  
Annamaria Vezzani ◽  
Gianluca Civenni ◽  
Massimo Rizzi ◽  
Antonella Monno ◽  
Silvia Messali ◽  
...  

1986 ◽  
Vol 20 (1) ◽  
pp. 82-88 ◽  
Author(s):  
Gregory L. Holmes ◽  
Donald A. Weber

2021 ◽  
Author(s):  
Wan-Yu Huang ◽  
Yen-Ling Lai ◽  
Ko-Hung Liu ◽  
Shankung Lin ◽  
Hsuan-Ying Chen ◽  
...  

Abstract BackgroundSystemic inflammation is a potent contributor to increased seizure susceptibility. However, less is known about the effects of systemic inflammation on blood-brain barrier (BBB) that affect neuron excitability. Necroptosis and inflammation are intimately associated in various neurological diseases. We hypothesized that necroptosis is involved in the mechanism underlying sepsis-associated neuronal excitability in BBB components.MethodsSystemic inflammation was induced by LPS. Seizure susceptibility of mice was measured by kainic acid intraperitoneal injection. Pharmacological inhibitors (C87 and GSK872) were used to block signaling of TNFα receptors and necroptosis. To identify the features of sepsis-associated response in the BBB and CNS, brain tissues of mice were obtained for assays of the necroptosis-related protein expression, and immunofluorescence staining for morphological changes of endothelia and glia. Microdialysis assay was also used to evaluate the changes of extracellular potassium and glutamate levels in brain.ResultsSignificant findings including induced increased seizure susceptibility and BBB endothelia necroptosis and leakage, Kir4.1 dysfunction, and microglia activation were observed in mice following LPS injection. Inhibition of TNFa receptor inhibitor C87 significantly attenuated increased kainic acid-induced seizure susceptibility and endothelia necroptosis and microglia activation, and restored kir4.1 protein expression, compared with those in controls. GSK872 (a RIP3 inhibitor) treatment, like C87, had consistent effects on these changes following LPS.ConclusionsOur results showed that TNFα-mediated necroptosis in BBB endothelia damage contributes to the development of increased seizure susceptibility in mice after systemic inflammation. Pharmacologic inhibition targeting this necroptosis pathway may provide a promising therapeutic approach to reduce sepsis-associated BBB dysfunction, astrocyte ion channel dysfunction, and subsequent neuronal excitability.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 1482
Author(s):  
Pavel Mareš ◽  
Lucie Kozlová ◽  
Anna Mikulecká ◽  
Hana Kubová

The GluN2B subunit of NMDA receptors represents a perspective therapeutic target in various CNS pathologies, including epilepsy. Because of its predominant expression in the immature brain, selective GluN2B antagonists are expected to be more effective early in postnatal development. The aim of this study was to identify age-dependent differences in the anticonvulsant activity of the GluN2B-selective antagonist Ro 25-6981 and assess the safety of this drug for the developing brain. Anticonvulsant activity of Ro 25-6981 (1, 3, and 10 mg/kg) was tested in a pentylenetetrazol (PTZ) model in infantile (12-day-old, P12) and juvenile (25-day-old, P25) rats. Ro 25-6981 (1 or 3 mg/kg/day) was administered from P7 till P11 to assess safety for the developing brain. Animals were then tested repeatedly in a battery of behavioral tests focusing on sensorimotor development, cognition, and emotionality till adulthood. Effects of early exposure to Ro 25-6981 on later seizure susceptibility were tested in the PTZ model. Ro 25-6981 was effective against PTZ-induced seizures in infantile rats, specifically suppressing the tonic phase of the generalized tonic–clonic seizures, but it failed in juveniles. Neither sensorimotor development nor cognitive abilities and emotionality were affected by early-life exposure to Ro 25-6981. Treatment cessation did not affect later seizure susceptibility. Our data are in line with the maturational gradient of the GluN2B-subunit of NMDA receptors and demonstrate developmental differences in the anti-seizure activity of the GluN2B-selective antagonist and its safety for the developing brain.


Neuroscience ◽  
2003 ◽  
Vol 117 (2) ◽  
pp. 391-395 ◽  
Author(s):  
Y Yoshihara ◽  
H Onodera ◽  
K Iinuma ◽  
Y itoyama

1988 ◽  
Vol 27 (2) ◽  
pp. 209-212 ◽  
Author(s):  
G.L. Holmes ◽  
J.L. Thompson
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document